Amivantamab in Adenoid Cystic Carcinoma (NCT05074940)

🧪 Interventions in This Study

• Amivantamab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (5 Sites)

• UC San Diego Moores Cancer Center — La Jolla, California
• Dana Farber Cancer Institute — Boston, Massachusetts
• Rogel Cancer Center - University of Michigan Health — Ann Arbor, Michigan
• Washington University - School of Medicine in St. Louis — St Louis, Missouri
• University of Cincinnati Medical Center — Cincinnati, Ohio

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Salivary Gland Cancer

• 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma — Boston, Massachusetts
• Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas — Atlanta, Georgia
• Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers — Boston, Massachusetts
• A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers — Boston, Massachusetts

Explore by condition: All Salivary Gland Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.